Biosurfactants as a Novel Additive in Pharmaceutical Formulations: Current Trends and Future Implications

2020 ◽  
Vol 21 (11) ◽  
pp. 885-901
Author(s):  
Shubham Thakur ◽  
Amrinder Singh ◽  
Ritika Sharma ◽  
Rohan Aurora ◽  
Subheet Kumar Jain

Background: Surfactants are an important category of additives that are used widely in most of the formulations as solubilizers, stabilizers, and emulsifiers. Current drug delivery systems comprise of numerous synthetic surfactants (such as Cremophor EL, polysorbate 80, Transcutol-P), which are associated with several side effects though used in many formulations. Therefore, to attenuate the problems associated with conventional surfactants, a new generation of surface-active agents is obtained from the metabolites of fungi, yeast, and bacteria, which are termed as biosurfactants. Objectives: In this article, we critically analyze the different types of biosurfactants, their origin along with their chemical and physical properties, advantages, drawbacks, regulatory status, and detailed pharmaceutical applications. Methods: 243 papers were reviewed and included in this review. Results: Briefly, Biosurfactants are classified as glycolipids, rhamnolipids, sophorolipids, trehalolipids, surfactin, lipopeptides & lipoproteins, lichenysin, fatty acids, phospholipids, and polymeric biosurfactants. These are amphiphilic biomolecules with lipophilic and hydrophilic ends and are used as drug delivery vehicles (foaming, solubilizer, detergent, and emulsifier) in the pharmaceutical industry. Despite additives, they have some biological activity as well (anti-cancer, anti-viral, anti-microbial, P-gp inhibition, etc.). These biomolecules possess better safety profiles and are biocompatible, biodegradable, and specific at different temperatures. Conclusion: Biosurfactants exhibit good biomedicine and additive properties that can be used in developing novel drug delivery systems. However, more research should be driven due to the lack of comprehensive toxicity testing and high production cost which limits their use.

Author(s):  
Priyanka Kriplani ◽  
Kumar Guarve

Background: Polymers are the backbone of modern pharmaceutical formulations and drug delivery technologies. Polymers that may be natural, synthetic, or semisynthetic are used to control the release of drugs in a pre-programmed fashion. The drug delivery systems are mainly prepared to enhance the bioavailability, site-specific release, sustained release, controlled release, i.e., to modify the release of drug from dosage form may be a tablet, capsule, etc. Objective: The objective of the present study is to overview the recent patents concerning the application of eudragit in the prevention of cancer and other ailments. Eudragit polymers are polymethacrylates and may be anionic, cationic, or non-ionic polymers of methacrylic acid, dimethyl-aminoethyl methacrylates, and methacrylic acid esters in varying ratios. Eudragit is available in various grades with solubilities at different pH, thus helping the formulators design the preparation to have a well-defined release pattern. Method: In this review, patent applications of eudragit in various drug delivery systems employed to cure mainly cancer are covered. Results : Eudragit has proved its potential as a polymer to control the release of drugs as coating polymer and formation of the matrix in various delivery systems. It can increase the bioavailability of the drug by site-specific drug delivery and can reduce the side effects/toxicity associated with anticancer drugs. Conclusion: The potential of eudragit to carry the drug may unclutter novel ways for therapeutic intercessions in various tumors.


2020 ◽  
Vol 11 (12) ◽  
pp. 1985-1997
Author(s):  
Peng Wei ◽  
Fabian H. Sobotta ◽  
Carolin Kellner ◽  
Damiano Bandelli ◽  
Stephanie Hoeppener ◽  
...  

Smart nano-carriers such as micelles, vesicles or nanoparticles constructed from amphiphilic polymers promise a new generation of drug delivery systems featuring localized and controlled release.


2021 ◽  
Author(s):  
Meagan Rhyne Moser ◽  
Christopher Anthony Baker

Biological and pharmaceutical analytes like liposomes, therapeutic proteins, nanoparticles, and drug-delivery systems are utilized in applications, such as pharmaceutical formulations or biomimetic models, in which controlling their size is often...


Pharmaceutics ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 1142
Author(s):  
Fátima García-Villén ◽  
César Viseras

The use of minerals as ingredients in health care products is a classical and active pharmaceutical subject [...]


Pathogens ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 245 ◽  
Author(s):  
Sartini Sartini ◽  
Andi Dian Permana ◽  
Saikat Mitra ◽  
Abu Montakim Tareq ◽  
Emil Salim ◽  
...  

In recent years, the emergence of newly identified acute and chronic infectious disorders caused by diverse combinations of pathogens, termed polymicrobial diseases, has had catastrophic consequences for humans. Antimicrobial agents have been clinically proven to be effective in the pharmacological treatment of polymicrobial diseases. Unfortunately, an increasing trend in the emergence of multi-drug-resistant pathogens and limited options for delivery of antimicrobial drugs might seriously impact humans’ efforts to combat polymicrobial diseases in the coming decades. New antimicrobial agents with novel mechanism(s) of action and new pharmaceutical formulations or delivery systems to target infected sites are urgently required. In this review, we discuss the prospective use of novel antimicrobial compounds isolated from natural products to treat polymicrobial infections, mainly via mechanisms related to inhibition of biofilm formation. Drug-delivery systems developed to deliver antimicrobial compounds to both intracellular and extracellular pathogens are discussed. We further discuss the effectiveness of several biofilm-targeted delivery strategies to eliminate polymicrobial biofilms. At the end, we review the applications and promising opportunities for various drug-delivery systems, when compared to conventional antimicrobial therapy, as a pharmacological means to treat polymicrobial diseases.


Materials ◽  
2021 ◽  
Vol 14 (4) ◽  
pp. 1042
Author(s):  
Katarzyna Winnicka

Development of new drug molecules is costly and requires longitudinal, wide-ranging studies; therefore, designing advanced pharmaceutical formulations for existing and well-known drugs seems to be an attractive device for the pharmaceutical industry [...]


2017 ◽  
Vol 34 (6) ◽  
pp. 1204-1216 ◽  
Author(s):  
Suellen M. T. Cavalcanti ◽  
Cláudia Nunes ◽  
Sofia A. C. Lima ◽  
José L. Soares-Sobrinho ◽  
Salette Reis

Sign in / Sign up

Export Citation Format

Share Document